Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy

Journal of Hematology & Oncology

He Lu³  Rémi Varin¹  Hong Li⁶  Anne Janin⁵  Lionel Cazin¹  Claudine Soria⁶  Jian Jin²  Jielin Liu⁴  Mariana Varna³  Charlène Dulong¹  Chaoquan Hu⁶  Jennifer Coelho-Martins⁶  Christelle Perrault⁶  Limin Huang⁶ 

[1] DIFEMA, Merci (EA 3829), Faculté de Médecine et de Pharmacie, Université de Rouen, F-76183 Rouen, France;School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214122 China;Sorbonne Paris Cité, Laboratoire de pathologie, UMR-S 728, Université Paris Diderot, Paris F-75010, France;Center of Tissue Engineering and Stem cells, Guiyang Medical University, 550004 Guiyang, China;AP-HP-Hôpital Saint-Louis, Laboratoire de pathologie–Paris, Paris F-75010, France;INSERM, U728-Paris F-75010, France

关键词: Anti-cancer therapy;    ATP-dependent transporter;    Endothelial cells;    Drug resistance;   

Others  :  804597
DOI  :  10.1186/1756-8722-6-49

 received in 2013-04-11, accepted in 2013-05-31,  发布年份 2013

【 摘 要 】

Background

Multidrug resistance (MDR) is one of the major problems in the treatment of cancer. Overcoming it is therefore expected to improve clinical outcomes for cancer patients. MDR is usually characterized by overexpression of ABC (ATP-binding cassette) protein transporters such as P-gp, MRP1, and ABCG2. Though the importance of ABC transporters for cancer cells is recognized, few studies have looked at its implications for the endothelial cells that are essential to tumor angiogenesis. This study investigated the expression and functions of these ABC transporters in endothelial cells in vitro and their potential contribution to cancer growth in mice.

Methods

Human micro vessel endothelial cells (HMEC-1) and human umbilical vein endothelial cells (HUVEC) were exposed to increasing doses of Doxorubicin (Dox) to induce ABC gene expression. Cell viability was then quantified by ³H-thymidine and MTS assay. Flow cytometry, qPCR, and western blot were used to detect mRNA and the protein expression of P-gp, MRP1, and ABCG2. The intracellular accumulation of Rhodamine 123 (Rho) was used to evaluate drug efflux function and the inhibitors for P-gp, ABCG2, and MRP1 were used to verify their respective roles in vitro. In an attempt to evaluate drug resistance in endothelial cells in vivo, athymic mice were treated with Dox for 15 days before a MDA-MB-435 tumor graft to observe subsequent changes in the inhibition curves of tumor growth in response to Dox treatment. Furthermore, endothelial cells from multiple sites in these mice were also isolated to estimate their P-gp expression by flow cytometry.

Results

Drug resistance in HMEC-1 and HUVEC was successfully induced by the addition of Dox to the culture media. Two stabilized subcell lines of HMEC1 (HMECd1 and HMECd2) showed 15- and 24-fold increases in resistance. Tests also showed that these induced endothelial cells were cross-resistant to the structurally unrelated drugs Daunorubicin, Vinblastine, and Etoposide. P-gp protein levels increased four and six fold in HMECd1 and HMECd2 as revealed by western blot. The qPCR demonstrated 3.4- and 7.2-fold increases in P-gp, and a slight increase in ABCG2, gene expression. The Rho accumulation within these cells was inversely correlated with the expression levels of P-gp. The inhibitors of P-gp, but not of ABCG2 or MRP1, were able to block the induced endothelial cell resistance to Dox. Furthermore, we also showed that injecting Dox into healthy mice induced an increase in P-gp expression in endothelial cells. Using these pretreated mice in a tumor growth experiment, we observed a dramatic diminution in the therapeutic efficiency of Dox treatment, suggesting implications for drug resistance in mice endothelial cells supporting tumor growth.

Conclusions

ABC transporter expression can be induced in endothelial cells in vitro. This study also indicates that P-gp plays an important role in the acquisition of resistance to Dox in endothelial cells and that this reduces the efficiency of chemotherapy.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
• [2]Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136:261-276.
• [3]Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
• [4]Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286.
• [5]Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary andmetastatic disease. Cancer Res 1992, 52:6702-4.
• [6]Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997, 15:39-48.
• [7]Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br J Cancer 1982, 45:136-139.
• [8]Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993, 66:181-196.
• [9]Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13:31-36.
• [10]Biedler JL, Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970, 30:1174-1184.
• [11]Harrison DJ: Molecular mechanisms of drug resistance in tumours. J Pathol 1995, 175:7-12.
• [12]Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
• [13]Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002, 2:48-58.
• [14]Dean M: The genetics of ATP-binding cassette transporters. Methods Enzymol 2005, 400:409-429.
• [15]Deeley RG, Westlake C, Cole SP: Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006, 86:849-899.
• [16]Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976, 455:152-162.
• [17]Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38:1277-1287.
• [18]Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
• [19]Linton KJ, Higgins CF: Structure and function of ABC transporters: the ATP switch provides flexible control. Pflugers Arch 2007, 453:555-567.
• [20]Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 1989, 86:695-698.
• [21]Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park) 1999, 13:183-7.
• [22]Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P glycoprotein. Cancer Chemother Pharmacol 1997, 40(Suppl):13-19.
• [23]Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000, 60:5761-5766.
• [24]Smit JW, Schinkel AH, Muller M, Weert B, Meijer DK: Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 1998, 27:1056-1063.
• [25]Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
• [26]Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, Doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987, 84:3004-3008.
• [27]Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M: Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999, 14:123-131.
• [28]Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, et al.: Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846.
• [29]Natarajan K, Xie Y, Baer MR, Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012, 83:1084-1103.
• [30]Scherrmann JM: Expression and function of multidrug resistance transporters at the blood–brain barriers. Expert Opin Drug Metab Toxicol 2005, 1:233-246.
• [31]Seetharaman S, Barrand MA, Maskell L, Scheper RJ: Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998, 70:1151-1159.
• [32]Bendayan R, Ronaldson PT, Gingras D, Bendayan M: In situlocalization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006, 54:1159-1167.
• [33]Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R: Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 2007, 24:1262-1274.
• [34]Zhang Y, Han H, Elmquist WF, Miller DW: Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000, 876:148-153.
• [35]Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, Scherrmann JM, De Waziers I, Declèves X: Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009, 77:897-909.
• [36]Hida K, Akiyama K, Ohga N, Maishi N, Hida Y: Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J Biochem 2013, 153:243-249.
• [37]Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, Inoue N, Shindoh M, Hida K: Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 2012, 180(3):1283-1293.
• [38]Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaïdis A, Opolon P, Connault E, Li H, Grenet C, Fauvel-Lafève F, Soria J, Legrand C, Soria C, Perricaudet M, Lu H: Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004, 64:2062-2069.
• [39]Jaffe E, Nachman R, Becker C, Minick C: Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973, 52:2745-2756.
• [40]Ji BS, He L, Liu GQ: Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci 2005, 77:2221-2232.
• [41]Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55:23-29.
• [42]Goler-Baron V, Assaraf YG: Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One 2011, 6:e16007.
• [43]Nakanishi T: Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 2007, 4:241-254.
• [44]Frank NY, Schatton T, Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010, 120:41-50.
• [45]Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
• [46]Baguley BC: Multidrug resistance in cancer. Methods Mol Biol 2010, 596:11-14.
• [47]Zhang JT: Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res 2007, 17:311-323.
• [48]Dudley AC, Klagsbrun M: Tumor endothelial cells join the resistance. Clin Cancer Res 2009, 15:4787-4789.